Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. Issue 6 (1st June 2022)
- Record Type:
- Journal Article
- Title:
- Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. Issue 6 (1st June 2022)
- Main Title:
- Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
- Authors:
- Lopez de Rodas, Miguel
Nagineni, Venkata
Ravi, Arvind
Datar, Ila J
Mino-Kenudson, Mari
Corredor, German
Barrera, Cristian
Behlman, Lindsey
Rimm, David L
Herbst, Roy S
Madabhushi, Anant
Riess, Jonathan W
Velcheti, Vamsidhar
Hellmann, Matthew D
Gainor, Justin
Schalper, Kurt A - Abstract:
- Abstract : Background: Tumor infiltrating lymphocytes (TILs) reflect adaptive antitumor immune responses in cancer and are generally associated with favorable prognosis. However, the relationships between TILs subsets and their spatial arrangement with clinical benefit from immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) remains less explored. Methods: We used multiplexed quantitative immunofluorescence panels to determine the association of major TILs subpopulations, CD8 + cytotoxic T cells, CD4 + helper T cells and CD20 + B cells, and T cell exhaustion markers, programmed cell death protein-1 (PD-1), lymphocyte-activation gene 3 (LAG-3) and T cell immunoglobulin mucin-3 (TIM-3) with outcomes in a multi-institutional cohort of baseline tumor samples from 179 patients with NSCLC treated with ICI. The analysis of full-face tumor biopsies including numerous fields of view allowed a detailed spatial analysis and assessment of tumor immune heterogeneity using a multiparametric quadratic entropy metric (Rao's Q Index (RQI)). Results: TILs were preferentially located in the stromal tissue areas surrounding tumor-cell nests and CD8 + T cells were the most abundant subset. Higher density of stromal CD8 + cytotoxic T cells was significantly associated with longer survival, and this effect was more prominent in programmed death ligand-1 (PD-L1) positive cases. The role of baseline T cell infiltration to stratify PD-L1 expressing cases was confirmed measuringAbstract : Background: Tumor infiltrating lymphocytes (TILs) reflect adaptive antitumor immune responses in cancer and are generally associated with favorable prognosis. However, the relationships between TILs subsets and their spatial arrangement with clinical benefit from immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) remains less explored. Methods: We used multiplexed quantitative immunofluorescence panels to determine the association of major TILs subpopulations, CD8 + cytotoxic T cells, CD4 + helper T cells and CD20 + B cells, and T cell exhaustion markers, programmed cell death protein-1 (PD-1), lymphocyte-activation gene 3 (LAG-3) and T cell immunoglobulin mucin-3 (TIM-3) with outcomes in a multi-institutional cohort of baseline tumor samples from 179 patients with NSCLC treated with ICI. The analysis of full-face tumor biopsies including numerous fields of view allowed a detailed spatial analysis and assessment of tumor immune heterogeneity using a multiparametric quadratic entropy metric (Rao's Q Index (RQI)). Results: TILs were preferentially located in the stromal tissue areas surrounding tumor-cell nests and CD8 + T cells were the most abundant subset. Higher density of stromal CD8 + cytotoxic T cells was significantly associated with longer survival, and this effect was more prominent in programmed death ligand-1 (PD-L1) positive cases. The role of baseline T cell infiltration to stratify PD-L1 expressing cases was confirmed measuring the T cell receptor-burden in an independent NSCLC cohort studied with whole-exome DNA sequencing. High levels of LAG-3 on T cells or elevated RQI heterogeneity index were associated with worse survival in the cohort. Conclusion: Baseline T cell density and T cell exhaustion marker expression can stratify outcomes in PD-L1 positive patients with NSCLC treated with ICI. Spatial immune heterogeneity can be measured using the RQI and is associated with survival in NSCLC. … (more)
- Is Part Of:
- Journal for immunotherapy of cancer. Volume 10:Issue 6(2022)
- Journal:
- Journal for immunotherapy of cancer
- Issue:
- Volume 10:Issue 6(2022)
- Issue Display:
- Volume 10, Issue 6 (2022)
- Year:
- 2022
- Volume:
- 10
- Issue:
- 6
- Issue Sort Value:
- 2022-0010-0006-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-06-01
- Subjects:
- immunotherapy -- lymphocytes, tumor-infiltrating -- lung neoplasms -- tumor biomarkers -- programmed cell death 1 receptor
Cancer -- Immunotherapy -- Periodicals
Cancer -- Immunological aspects -- Periodicals
Tumors -- Immunological aspects -- Periodicals
Immunotherapy -- Periodicals
616.99406105 - Journal URLs:
- http://www.immunotherapyofcancer.org ↗
https://jitc.bmj.com/ ↗
http://link.springer.com/ ↗ - DOI:
- 10.1136/jitc-2021-004440 ↗
- Languages:
- English
- ISSNs:
- 2051-1426
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21790.xml